Platform
Animer™ Binders
At the core of Animerra’s platform are our proprietary Animer™ binder modules — compact, single-domain antibody (sdAb) binding proteins derived directly from canine and feline antibody frameworks. Unlike approaches borrowed from camelid or other non-companion-animal sources, Animers are built on stabilized, species-matched VH domains that are natural to dogs and cats. This means they are inherently well-tolerated in the patients they are designed to treat, with minimal risk of immunogenicity.
Compact size
maximizing therapeutic efficacy with minimal dosing.
Capable of accessing cell-surface targets
and cryptic epitopes that are simply out of reach for traditional full-size IgG antibodies.
Opens target space
that has never before been available to animal health biologics.
Optimized mRNA Display
We discover Animers™ using an optimized form of mRNA display screening.
While others describe libraries with theoretical diversities of 10¹¹ or more, Animerra delivers verified screening diversity exceeding 10¹³ unique sequences — orders of magnitude beyond what phage display (10¹¹ theoretical maximum), yeast display (10¹⁰), or traditional repertoire libraries (10⁶) can achieve. Theoretical and actual are not the same thing: every display technology suffers attrition between what is possible on paper and what is successfully expressed and screened. We have closed that gap.
Our Libraries
Our proprietary library suite — spanning repertoire, synthetic, and semi-synthetic sequences — is built on stabilized canine and feline VH frameworks, ensuring that the diversity we screen reflects the natural biology of the species we treat. These are not generic or foreign scaffolds adapted after the fact; the canine and feline character of our Animers™ is built into the foundation of our discovery engine. The result is not only a more powerful screening platform, but one that produces better, more natural drug candidates from the outset.
mRNA display also confers a structural advantage: because the displayed protein is not tethered to a cell or phage surface, it avoids the steric hindrance that limits other display technologies when screening against cell-surface targets and cryptic epitopes. The combination of ultra-high verified diversity with the compact geometry of our Animer™ binders unlocks access to target classes that have historically been intractable for biologics — including GPCRs and ion channels. These challenging targets are now within reach.
AI-Powered Discovery
Animerra’s platform is purpose-built to harness and amplify the power of AI-driven discovery. The massive, high-quality datasets generated by our mRNA display screens — spanning trillions of unique sequences with associated binding information — create an ideal substrate for machine learning analysis. Where conventional display methods produce datasets too sparse or noisy to train meaningful models, the verified diversity and depth of our screens provide the signal clarity that AI tools require to perform.
We are actively deploying AI tools across multiple stages of our discovery workflow. Protein structure prediction models inform library design, enabling us to build libraries with conformations matched to the target and access binding geometries that would be difficult to define by sequence alone. Following each screen, AI-assisted sequence clustering and next-generation sequencing analysis allow us to extract value from the full depth of our data — surfacing high-quality binders that would be overlooked by enrichment-based ranking alone. Structure-based clustering tools further allow us to bin hits by predicted epitope and binding mode, giving us a clearer map of the target’s accessible binding landscape before we commit to lead selection.
Anibody™ Therapeutics
Animerra’s modular platform is designed to go beyond single-target binding. Our Animer™ binder modules assemble into Anibody™ therapeutic formats that can be configured for multi-valency, multi-specificity, or both — with each architecture tailored to the biology of the target. Because our building blocks are compact by nature, these multi-specific and multivalent constructs remain small enough to maximize the amount of therapeutic delivered in a minimal dosing volume, a meaningful practical advantage in veterinary medicine. The modularity of our platform means that new therapeutic configurations can be rapidly explored without rebuilding from scratch.
